Designates September 21-28, 2025, as Frontotemporal Degeneration Awareness Week in Louisiana
House Concurrent Resolution 48 designates September 21-28, 2025, as Frontotemporal Degeneration (FTD) Awareness Week in Louisiana. The resolution is primarily commemorative and educational: it recognizes FTD as a serious neurodegenerative disease, notes its connection to broader Alzheimer’s and related dementia planning, and encourages Louisianians to support efforts that increase awareness and improve treatment options.
The resolution includes background findings describing FTD as a terminal, incurable disease that affects speech, behavior, personality, motor skills, and cognition. It emphasizes that FTD is often misdiagnosed, can begin at a relatively young age, and imposes significant personal and financial burdens on patients and caregivers. The measure also highlights the role of the Association for Frontotemporal Degeneration and the need for greater public and governmental attention to the disease.
HCR 48 does not amend or create statutory law, impose regulatory requirements, or appropriate funds. Its legal effect is limited to formally designating a week of awareness in Louisiana and expressing legislative support for public education and advocacy related to FTD, dementia care, and treatment research. The resolution may help elevate visibility for patients, caregivers, health advocates, and organizations working on neurodegenerative disease awareness.
The overall sentiment around the resolution appears strongly supportive and noncontroversial. The Senate concurred unanimously, with a 36-0 vote, indicating broad bipartisan agreement on the value of recognizing FTD Awareness Week and promoting awareness of the disease. The bill’s tone is sympathetic and public-health oriented, focusing on patients, families, and caregivers rather than policy conflict.
No notable opposition or substantive controversy is reflected in the available record. Because the measure is a concurrent resolution honoring an awareness week, there were no committee transcripts indicating debate over costs, mandates, or legal changes. Any potential points of interest are informational rather than contentious, such as the emphasis on FTD’s misdiagnosis, early onset, and high care costs, which support the case for awareness but do not appear to have generated disagreement.